ROYALTY INTEREST ACQUISITION AGREEMENT Dated as of July 1, 2014 between Supernus Pharmaceuticals, Inc. and HealthCare Royalty Partners III, L.P.Royalty Interest Acquisition Agreement • July 8th, 2014 • Supernus Pharmaceuticals Inc • Pharmaceutical preparations • New York
This ROYALTY INTEREST ACQUISITION AGREEMENT is made and entered into as of July 1, 2014 by and between Supernus Pharmaceuticals, Inc., a Delaware corporation, and HealthCare Royalty Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (the “Agreement”).
ROYALTY INTEREST ACQUISITION AGREEMENT Dated as of December 28, 2017 by and among ELOBIX AB, as Seller, HEALTHCARE ROYALTY PARTNERS III, L.P., as Buyer and solely for the purposes of Section 5.08, Section 5.09 and Article VIII, ALBIREO PHARMA, INC.,...Royalty Interest Acquisition Agreement • March 27th, 2018 • Albireo Pharma, Inc. • Pharmaceutical preparations • New York
This ROYALTY INTEREST ACQUISITION AGREEMENT is made and entered into as of December 28, 2017 by and among Elobix AB, a limited liability company organized under the laws of Sweden, HealthCare Royalty Partners III, L.P., a limited partnership organized under the laws of the State of Delaware and, solely for the purposes of Section 5.08, Section 5.09 and Article VIII, Albireo Pharma, Inc. a Delaware corporation (the “Agreement”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Royalty Interest Acquisition Agreement • June 9th, 2020 • Albireo Pharma, Inc. • Pharmaceutical preparations • New York
AMENDMENT, dated as of June 8, 2020 (this “Amendment”), to the Royalty Interest Acquisition Agreement, dated as of December 28, 2017 (the “Acquisition Agreement”), by and among Elobix AB, a limited liability company organized under the laws of Sweden, (“Seller”), HealthCare Royalty Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“Buyer”) and, solely for the purposes of Section 5.08, Section 5.09 and Article VIII, Albireo Pharma, Inc. a Delaware corporation (“Seller Parent”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Acquisition Agreement.
CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. ROYALTY INTEREST ACQUISITION AGREEMENT Dated as of April 22, 2016 between Aviragen Therapeutics, Inc., Biota...Royalty Interest Acquisition Agreement • April 26th, 2016 • Aviragen Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This ROYALTY INTEREST ACQUISITION AGREEMENT is made and entered into as of April 22, 2016 by and between Aviragen Therapeutics, Inc. (formerly known as Biota Pharmaceuticals, Inc.), a Delaware corporation (“Aviragen”), Biota Holdings Pty Ltd (formerly known as Biota Holdings Limited), a corporation organized and existing under the laws of Victoria, Australia (“BHPL”), Biota Scientific Management Pty. Ltd., a corporation organized and existing under the laws of Victoria, Australia (“BSM”), and HealthCare Royalty Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (the “Agreement”).
ROYALTY INTEREST ACQUISITION AGREEMENT Dated as of February 25, 2021 between Akebia Therapeutics, Inc. and HealthCare Royalty Partners IV, L.P.Royalty Interest Acquisition Agreement • May 10th, 2021 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
